Guangdong Lifestrong Pharmacy Co., Ltd. (SHE:301111)
China · Delayed Price · Currency is CNY 21.30
-0.70 (-3.18%)
Sep 30, 2026, 3:04 PM CST
SHE:301111 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,408 | 3,045 | 2,605 | 3,930 | 3,139 | 7,720 | |
Market Cap Growth | 35.93% | 16.89% | -33.71% | 25.18% | -59.34% | - |
Enterprise Value | 2,943 | 2,785 | 2,277 | 3,600 | 2,612 | 7,557 |
Last Close Price | 21.30 | 19.00 | 16.20 | 24.29 | 19.31 | 47.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 575.11 | - | 625.75 | 117.30 | 93.93 | 135.01 |
PS Ratio | 11.19 | 9.68 | 9.35 | 13.44 | 11.08 | 22.07 |
PB Ratio | 4.51 | 4.05 | 3.40 | 5.05 | 4.14 | 10.28 |
P/TBV Ratio | 4.80 | 4.26 | 3.58 | 5.27 | 4.18 | 10.39 |
P/FCF Ratio | - | 3790.16 | - | - | 48.79 | 112.64 |
P/OCF Ratio | 199.33 | 287.83 | 811.83 | - | 44.92 | 107.78 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.66 | 8.85 | 8.17 | 12.31 | 9.22 | 21.60 |
EV/EBITDA Ratio | 289.82 | - | 420.47 | 102.25 | 74.32 | 101.29 |
EV/EBIT Ratio | - | - | - | 147.20 | 109.59 | 124.89 |
EV/FCF Ratio | - | 3466.84 | - | - | 40.59 | 110.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.09 | 0.02 | 0 | 0.00 |
Debt / EBITDA Ratio | 4.32 | - | 5.97 | 0.37 | 0.00 | 0.01 |
Debt / FCF Ratio | - | 56.62 | - | - | 0.00 | 0.02 |
Net Debt / Equity Ratio | -0.63 | -0.27 | -0.33 | -0.43 | -0.59 | -0.74 |
Net Debt / EBITDA Ratio | -127.34 | 22.29 | -46.16 | -9.40 | -12.84 | -7.41 |
Net Debt / FCF Ratio | 493.03 | -254.60 | 7.21 | 6.44 | -7.02 | -8.06 |
Asset Turnover | 0.33 | 0.34 | 0.31 | 0.34 | 0.34 | 0.58 |
Inventory Turnover | 1.50 | 1.48 | 0.97 | 1.23 | 1.51 | 2.01 |
Quick Ratio | 5.48 | 3.43 | 4.32 | 6.40 | 5.62 | 9.89 |
Current Ratio | 6.23 | 6.85 | 5.43 | 7.73 | 6.44 | 10.73 |
Return on Equity (ROE) | 0.41% | -1.20% | 0.16% | 4.23% | 4.43% | 10.65% |
Return on Assets (ROA) | -0.34% | -1.30% | -0.42% | 1.79% | 1.77% | 6.25% |
Return on Invested Capital (ROIC) | -0.60% | -3.56% | -1.24% | 5.66% | 9.07% | 26.79% |
Return on Capital Employed (ROCE) | -0.60% | -2.40% | -0.70% | 3.10% | 3.10% | 8.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.17% | -0.15% | 0.16% | 0.85% | 1.06% | 0.74% |
FCF Yield | -0.03% | 0.03% | -1.33% | -1.31% | 2.05% | 0.89% |
Dividend Yield | 0.23% | 0.26% | 0.31% | 0.41% | 0.52% | 0.34% |
Payout Ratio | 135.04% | - | 384.37% | 47.76% | 76.60% | - |
Buyback Yield / Dilution | -8.05% | -7.83% | 13.02% | -0.25% | -33.59% | 0.92% |
Total Shareholder Return | -7.82% | -7.57% | 13.33% | 0.17% | -33.07% | 1.26% |